newsTrodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk…
9 March 2022 | By Hannah Balfour (European Pharmaceutical Review)
Trodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk of disease progression or death in certain breast cancer patients.